Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASPIRIN CLAIM OF 44% REDUCTION IN RISK OF FIRST HEART ATTACK UNLIKELY

Executive Summary

ASPIRIN CLAIM OF 44% REDUCTION IN RISK OF FIRST HEART ATTACK UNLIKELY to be included in FDA professional labeling, based on the discussion of the Cardio-Renal Advisory Committee at their Oct. 6 meeting. Although the committee agreed to recommend the prophylactic use of aspirin to reduce the risk of primary myocardial infarction ("The Pink Sheet" Oct. 9, p. 2), members questioned whether the benefit would be as high for the general public as for the study population. The estimate that aspirin could reduce the risk of primary myocardial infarction (MI) by as much as 44% was a product of the Physicians' Health Study. The highly publicized trial of the effectiveness of low-dose aspirin in preventing first heart attacks whose results was first published in the July 20 New England Journal of Medicine ("The Pink Sheet," July 24, T&G 3). Julie Burin, co-principal investigator for the study, presented what she called "highly statistically significant" results of the study's 325 mg aspirin regimen on a patient population of 22,000 male U.S. physicians, aged 40-80. "There were 139 total MIs in the aspirin group, and 239 in the placebo group, yielding a 44% reduction in risk of myocardial infarction." The advisory panel was particularly concerned with the potential side effects of long-term asprin use, including increased risk of gastrointestinal disorders and cerebral hemorrhage. PHS data showed a rise in hemorrhagic strokes among the aspirin takers that Burin characterized as "borderline statistically significant," with 23 in the aspirin group and 12 in placebo. The committee also noted that the trial eliminated patients with gastric ulcers, rheumatism, gout; furthermore, it included a screening period during which patients exhibiting sensitivity to aspirin were dropped. "Patient selection for the trial basically would be expected to minimize the adverse effects of aspirin. . . How can you expect to generalize any adverse effect of aspirin from this study?" PHS researchers were asked. Although final wording for the professional labeling will not be determined until later this fall, the committee were unanimously in favor of limiting the indication to patients with the highest liklihood of heart attack: males over forty who have multiple risk factors for coronary heart disease but have not yet suffered an attack. In debating the remaining benefit to this patient population, the committee discussed the apparently above-average health of the doctors studied. For example, only 10% of the physicians in the trial smoked, compared to the 30% nationwide rate for U.S. males in their age group, according to PHS figures. Enrollees also had lower cholesterol and blood-pressure averages than the general public. "This is one of the lowest risk groups ever studied," stated committee Chairman Craig Pratt, MD, Baylor College of Medicine.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel